Business / Finance

RSS

AmpliPhi BioSciences completes sale of $18M of common stock in private placement financing

AmpliPhi BioSciences Corporation, the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has completed the sale of approximately $18 million of common stock in a private placement financing. The Company has issued an aggregate of 72,007,000 shares of the Company's common stock at a price per share of $0.25. Net proceeds from the placement are approximately $16.9 million.

24 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Polymer Technology acquires A1CNow family of products from Bayer Diabetes Care

Polymer Technology Systems, Inc., the U.S.-based manufacturer of the CardioChek family of point-of-care diagnostic products, announced today that it has acquired the A1CNow® family of products from Bayer Diabetes Care.

23 Dec 2013

Intrexon enters into definitive agreement to acquire Medistem

Intrexon Corporation, a leader in synthetic biology, today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. a pioneer in the development of Endometrial Regenerative Cells, universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung.

21 Dec 2013

TeamHealth Holdings announces acquisition of Professional Anesthesia Services

TeamHealth Holdings Inc., one of the nation's largest providers of outsourced physician staffing solutions for hospitals, announced the acquisition of the operations of Professional Anesthesia Services, LLP. Based in Omaha, Neb., Professional Anesthesia Services' physicians and certified registered nurse anesthetists manage more than 18,000 cases annually through anesthesia management services for Bergan Mercy Medical Center and three ambulatory surgery centers.

20 Dec 2013

CSA Medical announces closing of $16 million Series C financing

CSA Medical, Inc., the leading provider of advanced spray cryotherapy technology that flash freezes unwanted tissue inside the body, today announced that it has closed a $16 million Series C financing led by Ascension Ventures.

20 Dec 2013

Moberg Pharma acquires three OTC brands from Bayer HealthCare

On December 6, 2013, Moberg Pharma announced the acquisition of three Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC.

20 Dec 2013

Walgreen's net earnings increase $695M to 68.3% in fiscal 2014 first quarter

Walgreen Co. today announced earnings and sales results for the first quarter of fiscal year 2014 ended Nov. 30. Net earnings determined in accordance with generally accepted accounting principles (GAAP) for the fiscal 2014 first quarter were $695 million, a 68.3 percent increase from $413 million in the year-ago quarter.

20 Dec 2013

ORIX USA Health partners with TGen and TD2 to support Arizona's biomedical economy

ORIX USA Health and Life Sciences has completed an investment into Translational Drug Development (TD2) through the purchase of equity from the Translational Genomics Research Institute (TGen).

20 Dec 2013

PeptiDream signs Collaboration and License Agreement with Lilly

PeptiDream Inc, a Tokyo-based biopharmaceutical company, announced that they have entered into a Collaboration and License Agreement with US-based Eli Lilly and Company on 19 December 2013.

20 Dec 2013

RaySearch Laboratories, TomoTherapy terminate software licensing and development agreement

In 2007, RaySearch Laboratories AB and TomoTherapy Incorporated (now Accuray) entered into a software licensing and development agreement. Under the agreement, RaySearch developed a product named SharePlan, which was launched by TomoTherapy in 2009.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

MEDNAX acquires Neonatology Center of Winchester

MEDNAX, Inc., today announced the acquisition of Neonatology Center of Winchester, P.C., a neonatal physician group practice based in Winchester, Va. The practice will become part of MEDNAX's Pediatrix Medical Group division, a national group practice consisting of the nation's leading neonatal, maternal-fetal medicine, pediatric cardiology, and other pediatric specialty physicians.

19 Dec 2013

Nuvo Research, NovaMedica enter into agreement to market Pennsaid products in Russia

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC, a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States.

19 Dec 2013

National Mentor Holdings revenue increases to $15.6 million in Q4 2013

National Mentor Holdings, Inc. today announced its financial results for the fourth quarter and fiscal year ended September 30, 2013.

19 Dec 2013

MGC Diagnostics fourth quarter revenue increases 11% to $9.1 million

MGC Diagnostics Corporation, a global medical technology company, today reported financial results for the fourth quarter and year ended October 31, 2013.

19 Dec 2013

Merck and CNIO sign agreement to collaborate in area of cancer drug development

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development.

19 Dec 2013

Mazor Robotics gets first order for Renaissance system from Cordamed Biomedical Engineering

Mazor Robotics Ltd., the developer of Renaissance, an innovative surgical guidance system and its complementary products, announced today that it has received its first order for a Renaissance system from Cordamed Biomedical Engineering Inc., its distribution partner in Turkey. This represents the first Renaissance system order in Turkey, and Cordamed will install the system at a prominent hospital in Istanbul.

19 Dec 2013

Bristol-Myers Squibb signs agreement to sell global diabetes business

Bristol-Myers Squibb Company today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.

19 Dec 2013